How Is Growth Hormone Deficiency Diagnosed? Understanding the Testing Process

Establishing a growth hormone deficiency diagnosis usually requires more than symptoms or a single laboratory measurement. Because growth hormone is released in pulses rather than at a steady rate, one random blood test provides an incomplete clinical picture.

Instead, healthcare providers use a multi-step approach that may combine medical history, physical findings, growth patterns, laboratory testing, stimulation testing, and imaging when appropriate. Although the overall principles are similar, the diagnostic process differs between children and adults because the clinical signs, testing priorities, and interpretation of results change across the lifespan.

When Do Doctors Test for Growth Hormone Deficiency?

A healthcare professional may investigate the possibility of growth hormone deficiency when a patient’s growth pattern, symptoms, or medical history raises concern.

In children, findings such as height below the 3rd percentile, unusually slow growth velocity, downward crossing of height percentiles, or a substantial difference from expected height based on mid-parental height calculations can prompt further evaluation. These findings are not specific diagnostic criteria for growth hormone deficiency and may have many other causes.

Before attributing poor growth to a hormonal problem, doctors typically review the child’s medical history, family growth patterns, medications, nutritional status, and overall health. They may also evaluate for other causes of impaired growth, including thyroid disorders, celiac disease, chronic illness, nutritional deficiencies, and genetic conditions such as Turner syndrome.

In adults, clinical suspicion usually arises from medical history rather than growth patterns. Testing may be considered in patients with known or suspected hypothalamic or pituitary disease, previous pituitary surgery or radiation, structural lesions, or deficiencies involving other pituitary hormones.

Because symptoms such as low energy, reduced muscle mass, and changes in body composition are nonspecific, symptoms alone cannot confirm adult growth hormone deficiency.

Why a Random Growth Hormone Blood Test Is Not Enough

The pituitary gland releases growth hormone in episodic pulses rather than maintaining a constant concentration throughout the day. Secretion varies according to factors such as sleep, exercise, stress, fasting, age, and other physiological conditions.

Between these normal pulses, even healthy individuals may have very low or sometimes undetectable growth hormone concentrations.

For this reason, doctors generally cannot diagnose growth hormone deficiency from a single random growth hormone measurement. A low result could simply mean the blood sample was collected between normal secretory pulses rather than indicating a true deficiency.

Instead, clinicians rely on more stable biochemical markers and, when appropriate, controlled growth hormone stimulation testing.

IGF-1 and IGFBP-3 Blood Tests

Growth hormone is a peptide hormone that acts directly on multiple tissues and also stimulates the production of insulin-like growth factor 1 (IGF-1), particularly in the liver.

Unlike the pulsatile secretion of growth hormone, IGF-1 levels remain relatively stable throughout the day. This makes IGF-1 a useful marker for evaluating activity within the growth hormone–IGF-1 axis.

During pediatric evaluation, clinicians may also measure insulin-like growth factor-binding protein 3 (IGFBP-3). Both IGF-1 and IGFBP-3 are influenced by growth hormone activity, but neither can independently establish a diagnosis of growth hormone deficiency.

Results must be interpreted using appropriate reference ranges because IGF-1 and IGFBP-3 concentrations vary with age, sex, pubertal stage, nutrition, liver function, and overall health. Low levels can also occur in patients with poor nutrition, chronic illness, liver disease, or other conditions unrelated to primary growth hormone deficiency.

Therefore, low IGF-1 or IGFBP-3 results support further evaluation and may lead to growth hormone stimulation testing when appropriate. These measurements must always be interpreted within the patient’s broader clinical context.

Growth Hormone Stimulation Testing

What Happens During the Test?

A growth hormone stimulation test evaluates how strongly the pituitary gland can release growth hormone after exposure to a controlled pharmacological stimulus.

During the procedure, clinicians administer a stimulating agent selected according to the patient’s age, clinical circumstances, and local testing protocol. Depending on the setting, testing may involve agents such as insulin, glucagon, clonidine, arginine, or other validated stimuli.

Rather than relying on a single measurement, clinicians collect blood samples at several intervals after the stimulus is administered. These samples are used to determine the peak growth hormone response.

Different stimulation tests have different precautions and contraindications. Some protocols require particularly close medical supervision, so the appropriate test is selected according to the individual patient’s health and clinical situation.

How Are the Results Interpreted?

Once the test is complete, clinicians evaluate the peak growth hormone response alongside the patient’s medical history, physical findings, IGF-1 levels, and other clinical evidence.

There is no single universal cutoff that applies to every growth hormone stimulation test. Interpretation depends on factors such as the stimulation agent used, the specific laboratory assay, the patient’s age, body composition, pubertal status, and overall likelihood of pituitary disease.

Body composition can be particularly important in adults. Higher body mass index (BMI) can blunt stimulated growth hormone responses. For some testing protocols, clinicians therefore use BMI-specific diagnostic thresholds to reduce the risk of incorrectly classifying an overweight or obese patient as growth hormone deficient.

Because of these variables, stimulation-test results must be interpreted together with the patient’s broader clinical picture rather than judged from a laboratory number alone.

Bone Age X-Rays and Pituitary MRI

Laboratory testing is only part of the diagnostic process. Depending on the patient’s age, growth pattern, and medical history, doctors may also use imaging to evaluate skeletal development or investigate abnormalities involving the pituitary gland and hypothalamus.

Bone Age in Children

A bone age X-ray may be included in the evaluation of children with short stature or abnormal growth.

Typically, clinicians obtain an X-ray of the left hand and wrist and compare skeletal development with standardized reference images, often using the Greulich-Pyle method, to estimate skeletal maturity.

Delayed bone age can provide useful information about a child’s growth pattern, but it is not specific to growth hormone deficiency. Delayed skeletal maturation may also occur with constitutional delay of growth and puberty, hypothyroidism, chronic disease, and other conditions.

For this reason, bone age is interpreted as one component of the broader diagnostic assessment.

Why Doctors May Order a Pituitary MRI

When growth hormone deficiency is diagnosed or strongly suspected, a pituitary MRI may be used to evaluate the hypothalamic-pituitary region.

MRI can identify structural abnormalities such as pituitary tumors, congenital abnormalities, pituitary stalk abnormalities, or other lesions that could contribute to impaired hormone production.

Importantly, MRI generally helps clinicians investigate the underlying cause of growth hormone deficiency rather than independently proving that the hormonal deficiency exists.

The timing of MRI depends on the clinical situation. Some patients may already have known pituitary disease before hormonal testing begins, while others undergo imaging after biochemical findings raise concern about an underlying structural cause.

How Diagnosis Differs Between Children and Adults

The diagnostic priorities for growth hormone deficiency differ significantly between children and adults.

In pediatric care, the evaluation focuses heavily on growth. Doctors consider height, growth velocity, changes in growth percentiles, expected height based on parental stature, pubertal development, bone age, and biochemical markers such as IGF-1 and, in some cases, IGFBP-3.

Growth hormone stimulation testing may then be used when the overall clinical picture supports the possibility of deficiency.

In adults, evaluation is usually driven more by evidence of hypothalamic or pituitary disease than by symptoms alone. Changes in body composition, energy levels, exercise capacity, or quality of life may occur with adult growth hormone deficiency, but these symptoms overlap with many other medical conditions.

Growth hormone stimulation tests are also interpreted differently in adults and children. Diagnostic thresholds depend on the specific stimulation protocol, laboratory assay, clinical context, and, for some adult tests, factors such as BMI. Pediatric and adult cutoff values therefore should not be directly compared without considering the particular test being used.

How a Confirmed Diagnosis Guides Treatment

Once growth hormone deficiency has been established and the underlying cause has been evaluated, an endocrinologist can determine whether growth hormone replacement therapy is appropriate.

Treatment decisions depend on factors such as the patient’s age, severity of deficiency, underlying pituitary condition, other hormone deficiencies, contraindications, and overall health.

For eligible patients, treatment options include recombinant human growth hormone. Daily somatropin products such as Omnitrope are among the formulations used in clinical practice for appropriate children and adults with growth hormone deficiency. Longer-acting growth hormone formulations may also be available for certain patients.

Treatment is individualized rather than prescribed solely because of a low laboratory result. Patients receiving growth hormone therapy require ongoing medical monitoring so clinicians can evaluate treatment response, adjust dosing when necessary, and monitor for potential adverse effects or changes in other hormone requirements.

Why Test Results Need to Be Interpreted Together

In most cases, growth hormone deficiency cannot be diagnosed from a single laboratory number, standalone symptom, or isolated period of slowed growth.

Instead, clinicians integrate multiple sources of information. These may include medical and family history, physical examination, growth patterns in children, IGF-1-related measurements, stimulation testing when indicated, evaluation of other pituitary hormones, bone age assessment, and pituitary imaging when clinically appropriate.

Clinicians must also evaluate for alternative explanations for abnormal growth or nonspecific symptoms. In children, these may include nutritional problems, thyroid disease, celiac disease, chronic systemic illness, constitutional growth delay, or genetic conditions such as Turner syndrome. In adults, symptoms may overlap with metabolic conditions, sleep disorders, medication effects, other endocrine disorders, and numerous other health problems.

There are also selected clinical situations in which conventional stimulation testing may not be necessary, particularly when strongly supportive structural, genetic, or multiple pituitary-hormone findings are already present.

For this reason, growth hormone deficiency diagnosis requires an integrated clinical assessment rather than a rigid testing formula. Evaluation and interpretation are generally best performed by clinicians experienced in pediatric or adult endocrinology, who can determine whether true growth hormone deficiency is present and investigate the underlying cause before treatment is considered.